ArticleFrontiers in oncology2024
VIBE: an R-package for VIsualization of Bulk RNA Expression data for therapeutic targeting and disease stratification.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Development of cancer treatments such as antibody-based therapy relies on several factors across the drug-target axis, including the specificity of target expression and characterization of downstream signaling pathways. While existing tools for analyzing and visualizing transcriptomic data offer evaluation of individual gene-level expression, they lack a comprehensive assessment of pathway-guided analysis, relevant for single- and dual-targeting therapeutics. Here, we introduce VIBE (VIsualization of Bulk RNA Expression data), an R package which provides a thorough exploration of both individual and combined gene expression, supplemented by pathway-guided analyses. VIBE's versatility proves pivotal for disease stratification and therapeutic targeting in cancer and other diseases. Results: VIBE offers a wide array of functions that streamline the visualization and analysis of transcriptomic data for single- and dual-targeting therapies. Its intuitive interface allows users to evaluate the expression of target genes and their associated pathways across various cancer indications, aiding in target and disease prioritization. Metadata, such as treatment or number of prior lines of therapy, can be easily incorporated to refine the identification of patient cohorts hypothesized to derive benefit from a given drug. We demonstrate how VIBE can be used to assist in indication selection and target identification in three user case studies using both simulated and real-world data. VIBE integrates statistics in all graphics, enabling data-informed decision-making. Conclusions: VIBE facilitates detailed visualization of individual and cohort-level summaries such as concordant or discordant expression of two genes or pathways. Such analyses can help to prioritize disease indications that are amenable to treatment strategies such as bispecific or monoclonal antibody therapies. With this tool, researchers can enhance indication selection and potentially accelerate the development of novel targeted therapies with the goal of precision, personalization, and ensuring treatments align with an individual patient's disease state across a spectrum of disorders. Explore VIBE's full capabilities using the vignettes on the GitLab repository (https://gitlab.com/genmab-public/vibe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.